These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 1455403)
1. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403 [TBL] [Abstract][Full Text] [Related]
2. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients. Nurmohamed MT; Knipscheer HC; Stevens P; Krediet RT; Roggekamp MC; Berckmans RJ; ten Cate JW Clin Nephrol; 1993 Mar; 39(3):166-71. PubMed ID: 8462205 [TBL] [Abstract][Full Text] [Related]
3. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis. Ryan KE; Lane DA; Flynn A; Shepperd J; Ireland HA; Curtis JR Thromb Haemost; 1991 Sep; 66(3):277-82. PubMed ID: 1745997 [TBL] [Abstract][Full Text] [Related]
4. Experimental studies on the relative efficacy of dermatan sulphate and heparin as antithrombotic agents. Merton RE; Thomas DP Thromb Haemost; 1987 Oct; 58(3):839-42. PubMed ID: 3433248 [TBL] [Abstract][Full Text] [Related]
5. Potentiation of the antithrombotic action of dermatan sulphate by small amounts of heparin. Thomas DP; Gray E; Merton RE Thromb Haemost; 1990 Oct; 64(2):290-3. PubMed ID: 2270536 [TBL] [Abstract][Full Text] [Related]
6. Individualized anticoagulation with dermatan sulphate for haemodialysis in chronic renal failure. Boccardo P; Melacini D; Rota S; Mecca G; Boletta A; Casiraghi F; Gianese F Nephrol Dial Transplant; 1997 Nov; 12(11):2349-54. PubMed ID: 9394322 [TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparin in haemodialysis for chronic renal failure: dose finding study of CY222. Ireland H; Lane DA; Flynn A; Pegrum AC; Curtis JR Thromb Haemost; 1988 Apr; 59(2):240-7. PubMed ID: 2838924 [TBL] [Abstract][Full Text] [Related]
8. Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation. Ireland HA; Boisclair MD; Lane DA; Thompson E; Curtis JR Clin Nephrol; 1991 Jan; 35(1):26-33. PubMed ID: 1826095 [TBL] [Abstract][Full Text] [Related]
9. Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients. Vitale C; Berutti S; Bagnis C; Soragna G; Gabella P; Fruttero C; Marangella M J Nephrol; 2013; 26(1):158-63. PubMed ID: 22419236 [TBL] [Abstract][Full Text] [Related]
10. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450 [TBL] [Abstract][Full Text] [Related]
11. Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy. Vitale C; Verdecchia C; Bagnis C; Ganzaroli M; Giorcelli G; Marangella M J Nephrol; 2008; 21(2):205-12. PubMed ID: 18446715 [TBL] [Abstract][Full Text] [Related]
13. Effects of heparin, dermatan sulfate and of their association on the inhibition of venous thrombosis growth in the rabbit. Carrie D; Caranobe C; Gabaig AM; Larroche M; Boneu B Thromb Haemost; 1992 Dec; 68(6):637-41. PubMed ID: 1287877 [TBL] [Abstract][Full Text] [Related]
14. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study. Naumnik B; Pawlak K; Myśliwiec M Thromb Res; 2009 Feb; 123(4):631-6. PubMed ID: 18234290 [TBL] [Abstract][Full Text] [Related]
15. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not. Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927 [TBL] [Abstract][Full Text] [Related]
16. Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens. Sabry A; Taha M; Nada M; Al Fawzan F; Alsaran K Blood Coagul Fibrinolysis; 2009 Jan; 20(1):57-62. PubMed ID: 20523166 [TBL] [Abstract][Full Text] [Related]
17. [Dermatan sulfate and the prevention of experimental venous thrombosis]. Desnoyers P; Bara L; Samama M Pathol Biol (Paris); 1989 Jun; 37(6):759-67. PubMed ID: 2674877 [TBL] [Abstract][Full Text] [Related]
18. Equivalent effective doses of heparin and low molecular weight heparin(oid)s in haemodialysis for chronic renal failure. Lane DA; Ireland H; Tew CJ; Flynn A; Curtis JR Acta Chir Scand Suppl; 1988; 543():101-4. PubMed ID: 2847457 [TBL] [Abstract][Full Text] [Related]
19. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation. Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253 [TBL] [Abstract][Full Text] [Related]
20. Human pharmacokinetics and pharmacodynamics of MF 701 dermatan sulfate administered by continuous intravenous infusion. Agnelli G; Cosmi B; Renga C; Federici F; Nenci GG; Houin G; Gianese F Thromb Haemost; 1990 Oct; 64(2):256-9. PubMed ID: 2270533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]